All posts by imreal

The Consulting Report’s Top 25 Operations Consultants and Leaders of 2023


The Consulting Report is pleased to announce The Top 25 Operations Consultants and Leaders of 2023. The global economy has faced no shortage of interconnected challenges in the past several years, from a seemingly never-ending pandemic, to armed conflicts, to ongoing supply chain woes. The 25 exceptional people on this year’s list have earned their places thanks to their commitment to optimizing their clients’ value chains, countering the many challenges facing businesses with innovation and unparalleled expertise across a range of practice areas. Often, they are not just mitigating the effects of difficult situations, but enacting transformational change within businesses.

Some of the distinguished leaders on this year’s list include Jim Kilpatrick, Partner and Global Supply Chain & Network Operations Leader for Deloitte, who has led his firm’s perspectives, initiatives, and investments to help keep critical global supply chains flowing during disruption and volatility. Meanwhile, in 2022, PwC UK’s Lead Partner of Supply Chain and Operations, Alistair Kett, led the acquisition of Olivehorse, a leading consultancy specializing in supply chain management, which strengthened PwC’s FT Gold Medal ranked supply chain capability. And Gautam Narayan, Director in Slalom’s Global Supply Chain practice, has helped grow Slalom’s fledgling supply chain capabilities into a multimillion-dollar business.

The awardees on this year’s list lead from a host of positions, from Managing Director to Partner, Executive Vice President, and Principal, among others. What they share is their dedication to optimizing business operations for their clients, setting them up for growth now and into the future. Please join us in celebrating The Top 25 Operations Consultants and Leaders of 2023.

Jim Kilpatrick (Deloitte), Dharmendra Patwardhan (Capgemini), Fredrik de Maré (FTI Consulting), Glenn Steinberg (EY), Alistair Kett (PwC UK), Takshay Aggarwal (IBM), Gautam Narayan (Slalom), James Hannah (General Dynamics Information Technology), Jose Bleda (Accenture), Andrew Underwood (KPMG), Chris Monk (Protiviti), Jeree Hanavec (World Wide Technology), Bernd Schreiber (Arthur D. Little), Daniel Swan (McKinsey & Company), Allison Kahler (Bain & Company), Jeffery Gallart (Teneo), Michael Lierow (Oliver Wyman), Ben YoKell (Grant Thornton), Andrew Owen (Alvarez & Marsal), Jeffrey Groux (Raytheon Technologies), Geoff Ibbotson (Atos), Ankit Tiwari (Tata Consultancy Services), Corey Biven (SAIC), Claire Brockbank (QinetiQ), Casey Chapman (RSM US).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email:

ISET celebrates 35th anniversary meeting with nearly 1,000 registrants, record-breaking number of research submissions, sold out Exhibit Hall


ISET logo

HMP Global’s International Symposium on Endovascular Therapy is the premier arena for pioneering and practical endovascular education.

For its 35th annual gathering, HMP Global’s International Symposium on Endovascular Therapy (ISET) received a record-breaking amount of research submissions, welcomed nearly 1,000 registrants from around the globe, and hosted more than 40 companies in its sold-out Exhibit Hall, solidifying its position as the premier arena for pioneering and practical endovascular education.

ISET 2023 was held January 16-19 in Miami Beach, Fla., and welcomed the current and future legends in the field to explore groundbreaking techniques, technologies, and procedures while exchanging discussion and debate that ultimately drives patient care forward.

ISET’s founder and course director is Barry T. Katzen, MD, FACC, FACR, FSIR, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute; Chief Medical Innovation Officer, Baptist Health South Florida; and professor and founding chairman of the Department of Radiology at Florida International University, Herbert Wertheim College of Medicine in Miami.

“From the group that pioneered live case education, ISET has grown tremendously since the first meeting 35 years ago,” Katzen said. “Now as the leading meeting in endovascular therapy, ISET brings together a multidisciplinary faculty and audience to discuss groundbreaking techniques, implement change, and improve patient care. As the field continues to evolve, so will ISET. We are encouraged by the passion and energy exuded at this year’s conference and will continue to provide innovative education in the years to come.”

This year, 153 research abstracts were submitted for presentation, shattering previous records. All abstracts underwent blind peer review for quality of research, educational or scientific content, logical presentation, and impact on healthcare. Cutting-edge research e-posters were displayed on multimedia screens in the poster area of the Exhibit Hall at ISET, and late-breaking data was presented at the first major endovascular meeting in 2023.

This year’s award winners include:


  • Young Investigator Award (abstract award)


Title: “Effects of Changes in Volume Status in Patients with May-Thurners”

Author: Lauren Conway, MD, venous vascular surgery fellow, University of Maryland Medical Center

  • Best Poster Award (abstract award)


Title: “Time to Mechanical Thrombectomy Does Not Impact In-Hospital Outcomes for Acute Submassive Pulmonary Embolism”

Authors: Zain M. Khazi, MD, resident physician, University of Missouri-Columbia; and Ambarish Bhat, MD, assistant professor of radiology, University of Missouri-Columbia

  • Charles Tegtmeyer Annual Lecture: Past, Present and Future of Carotid Stenting


Presented by William A. Gray, MD, FACC, FSCAI, System Chief, Division of Cardiovascular Diseases of Main Line Health; and President, Lankenau Heart Institute


John Kaufman, MD, MS, FSIR, Chair, Department of Interventional Radiology of Dotter Interventional/OHSU

ISET 2023 was strengthened through continued endorsement from the Society of Interventional Radiology (SIR), continued partnership with the Society for Vascular Medicine (SVM), and a recently added educational partnership with the Society for Vascular Surgery (SVS), which collaborated on overall programming and provided two new vascular surgery Course Directors to this year’s expert lineup. With the support of these partnerships, ISET featured a bold scientific program covering the complete landscape of endovascular therapy practice and challenges.

Participants joined ISET 2023 from more than 20 countries around the globe for an educational program presented by more than 85 of the world’s foremost faculty presenters. Programming included focused symposia, “Essentials of Endovascular Therapy” co-developed by SVM, and “Non-Invasive Vascular Diagnosis,” during the pre-symposium day, and an informative Town Hall on “The Movement of Endovascular Procedures to the Ambulatory Space,” supported by an educational grant from Philips.

Live cases were presented by Miami Cardiac & Vascular Institute, University Hospital Leipzig, University of Pennsylvania, and Advanced Cardiac & Vascular Centers for Amputation Prevention. The educational agenda also featured dedicated sessions on PAD, embolotherapy, CLI, venous, PE, clot management, and an aortic update.

More than 40 supporting companies filled the ISET’s sold-out Exhibit Hall, offering attendees opportunities to learn about a wide range of services and equipment to best serve their needs and improve patient care.

ISET offered the opportunity to earn more than 40 CME/CNE credits through its Maximum Value Package. Clinicians who were not able to join in person may register for the MVP package and receive accredited session recordings on-demand, accessible in early February and available for 90 days.

For more information, visit iset.org.

ABOUT HMP GLOBAL 

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com

ISPE Announces Leaders from the White House, FDA, Merck, Catalent, & More at Facilities of the Future Conference


The International Society for Pharmaceutical Engineering (ISPE) announced keynote speakers for the 2023 ISPE Facilities of the Future Conference, taking place 31 January–1 February 2023 in North Bethesda, Maryland, USA, and virtually. This signature event brings together top pharmaceutical industry and regulatory leaders who will provide an actionable understanding of transformational technologies and their application across the breadth of biologics and pharmaceutical manufacturing facilities.

The 2023 ISPE Facilities of the Future Conference features a dynamic line-up of thought-provoking keynote presentations led by some of the most prominent names in the pharmaceutical industry.

Confirmed Keynote Speakers:

  • Matthew Hepburn, M.D., Senior Advisor to the OSTP Director on Pandemic Prevention, U.S. Office of Science and Technology Policy, Executive Office of the President
  • Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, CBER/FDA
  • Arlene Joyner, MS PMP, CSSGB, Branch Chief, CDMO Network, PCI/BARDA/ASPR/HHS
  • Thomas Warf, Expert Consultant, DHHS/OS/ASPR/BARDA
  • Jeffrey Baker, PhD, Retired, Former Regulator, FDA/CDER
  • Kerren Bergman, CEO, Hyde Engineering + Consulting Inc
  • Jim Collins, President, Pharmaceutical Delivery Systems LLC
  • Patricia Hurter, PhD, CEO, Lyndra Therapeutics
  • Martin Johnson, PhD, Vice President, Engineering, Synthetic Molecule Design and Development, Eli Lilly
  • John Machulski, VP, Engineering, Biologics & CGT, Catalent
  • James Stephanou, VP, Global Engineering Solutions, Merck

To learn more about this event and to register, visit ISPE.org/FOF23.

About ISPE

The International Society for Pharmaceutical Engineering (ISPE) is the world’s largest nonprofit association serving its members through leading scientific, technical, and regulatory advancement across the entire pharmaceutical lifecycle. The 20,000+ members of ISPE provide solutions to complex pharmaceutical industry challenges through innovation, member and workforce development, and technical, regulatory, and compliance collaborations in more than 120 countries worldwide. Founded in 1980, ISPE has its worldwide headquarters and training center in North Bethesda, Maryland, USA, and its operations center in Tampa, Florida, USA. For more information, visit ISPE.org.

Share article on social media or email:

$1.3 Billion Liquid Biopsy Market the Present and Future of Clinical Oncology


“Industry growth through 2027 will be driven by a shift toward personalized medicine, and growing acceptance of liquid biopsy technologies by the medical community.” – Kalorama Information

The global market for liquid biopsy diagnostic tests reached an estimated $1,267 million ($1.3 billion) in 2022, led by demand for diagnostics in guiding therapeutic decisions. The market is forecast to almost triple over the next several years, approaching $3.9 billion in 2027, according to medical market research firm Kalorama Information in the new report The World Market for Liquid Biopsy, 2023.

Liquid biopsies are a set of minimally invasive diagnostic methods that analyze tumor-derived materials that can be found circulating in biological fluids, to provide information for the diagnosis, treatment, and monitoring of cancer. The liquid biopsy market can be segmented by the type of analyte detected and analyzed. There are four main categories: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and other analytes, and multiple analytes. ctDNA-based tests represent the bulk of the market.

The market for liquid biopsy testing is in its early stages. As with many new technologies, the adoption rate of liquid biopsy testing is following a curve pattern, where early adoption will occur at a slower rate, but quickly pick up pace. The liquid biopsy market has reached the point that the pace of adoption is gaining momentum, and will rapidly increase over the forecast period through 2027.

Growth of the overall market revenues is expected to be propelled by several factors, including: the introduction of new products for various clinical applications, in particular therapy guidance and early diagnosis; the rising incidence and prevalence of cancer in most major markets; and growing awareness among clinicians and patients about less-invasive diagnostic and monitoring technologies.

“Obviously, tissue biopsies and imaging techniques remain the current standards of care in the diagnosis of solid tumors. However, they have risks and limitations, some of which can be overcome by the use of liquid biopsy in clinical oncology, as an alternative or complementary technique to the current standards of care,” says Bruce Carlson, publisher of Kalorama Information, a subsidiary of Science and Medicine Group.

Liquid biopsy testing has many potential applications in aspects of clinical oncology, including:

  • as an early detection and diagnosis/screening
  • as an alternative testing method when tissue biopsy is difficult/impossible, or when the primary site of metastatic disease is unknown
  • for therapy personalization and monitoring – by molecular characterization of a patient’s disease, clinicians can select the optimal course of therapy and monitor efficacy over time, as well as quickly react to adjust therapy should treatment resistance arise
  • for disease monitoring – to observe disease progression, tumor evolution, residual disease, and early detection of recurrence
  • for prognosis of disease

North America, particularly the United States, is the greatest source of demand for liquid biopsy testing, followed by Europe. Liquid biopsy-based testing is gaining acceptance by third-party payors in the US, making testing more accessible to patients. The majority of companies in the market are based in the US. Many focus their attention and marketing efforts exclusively on the US market. Meanwhile, in Europe, a significant proportion of liquid biopsy tests have been granted CE-IVD marking, granting them market access throughout the European Union, as well as other countries that recognize the CE-mark, in Europe and beyond.

Despite trailing North America and Europe, the Asia Pacific region is ripe with intrigue and opportunity. In the Asia Pacific region, the incidence of cancer is rising, but so is healthcare spending. Accordingly, companies in the liquid biopsy space are beginning to increase their presence in the Asia Pacific market. Slowly, new companies are emerging in the region, while more established companies are expanding their presence through regional offices or strategic partnerships.

PURCHASING THE REPORT

Dramatic changes have occurred in the liquid biopsy market, necessitating a resource to provide perspective on the market opportunity. This new report from Kalorama assesses the liquid biopsy market now and in 2027. The report can be useful for business planning, market share assessment, competitive research, and due diligence for mergers and acquisitions and other partnerships.

For more information or to purchase the market research report “The World Market for Liquid Biopsy, 2023,” visit: https://kaloramainformation.com/product/the-world-liquid-biopsy-market-2023/.

ABOUT KALORAMA INFORMATION

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Los Angeles Facial Plastic Surgeon Dr. Jacob Sedgh Recognized as a 2023 Top Patient Rated Doctor by Find Local Doctors


News Image

“It is such an honor to be recognized once again by Find Local Doctors. Providing my patients with beautiful, natural-looking results is always my goal,” says Dr. Sedgh.

A true leader in the world of aesthetic surgery, board-certified facial plastic surgeon, Dr. Jacob Sedgh, has impressive credentials and a superior level of training, coupled with a natural eye for balance and harmony. Dr. Sedgh offers his talent and skill to deliver excellence all areas of facial plastic surgery, ranging from traditional rhinoplasty procedures to reconstructive surgery on cancer patients. Find Local Doctors has selected Dr. Jacob Sedgh for this award as a result of his five-star ratings and exceptional reviews from patients across multiple online sources. Find Local Doctors is a user-friendly online directory, helps consumers connect with skilled physicians in their area. Dr. Sedgh has a deep understanding of facial aesthetics and consistently achieves results of outstanding quality that exceed the expectations of his patients. He provides a wide range of surgical and non-surgical treatments, which can often be combined to achieve optimal results, and he offers expertise in nose surgery (rhinoplasty), eyelid surgery (blepharoplasty), facelifts and ear surgery (otoplasty) and more. He has authored numerous medical articles and lectures at major seminars and conferences across the globe. Dr. Sedgh applies cutting-edge techniques to develop uniquely tailored treatments to address the specific needs of his patients.

“It is such an honor to be recognized once again by Find Local Doctors. Providing my patients with beautiful, natural-looking results is always my goal,” says Dr. Sedgh.

More about Dr. Jacob Sedgh:

With the benefit of two decades of medical training and practical experience at top medical institutions in the United States, Dr. Jacob Sedgh merges mastery of medical knowledge and surgical skills with the attention and perfection of a sculptor, delivering highly-personalized patient care. Dr. Sedgh attended the University of California, San Diego School of Medicine, receiving honors and recognition signifying his achievements as a top-tier graduate and completed a surgical internship at the University of California, San Francisco. He then finished his residency in otolaryngology and head and neck surgery at the prestigious University of Pittsburgh Medical Center, which is ranked third in the nation in head and neck surgery training. Patients can be confident they will receive the most advanced techniques and state-of-the-art technology from Dr. Sedgh at his clinic, located at 9201 Sunset Blvd, Suite 404 in West Hollywood, CA. For more information or to schedule a consultation, please call 310-888-2884 or visit http://www.sedghplasticsurgery.com.

Share article on social media or email:

Slone Partners Places Amy Levin as Vice President of Regulatory Affairs at Mainz Biomed


MainBiomed

“Amy Levin is an extremely accomplished and highly respected regulatory affairs specialist with a stellar history of high performance across multiple organizations,” said Slone Partners President Tara Kochis.

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and healthcare companies, has announced the placement of Amy Levin as Vice President of Regulatory Affairs at Mainz Biomed, a biomedical company that develops market-ready molecular genetic diagnostic solutions for life-threatening conditions.

In her new role, Levin will be charged with guiding the implementation and regulatory, clinical trial, and quality initiatives that are related to in vitro diagnostics. She will also contribute to key milestones for the FDA submission process for ColoAlert, the company’s highly efficacious and easy-to-use DNA-based detection test for colorectal cancer (CRC).

Levin has a successful track record of leading and collaborating with cross-functional teams and regulatory authorities to author, manage, and review required reports of the U.S. Food and Drug Administration (FDA) and international regulatory submissions. Previously, she served as Director of International Regulatory Affairs at Roche Molecular Systems after serving in several other roles with increasing leadership responsibilities within the company. She has also held other regulatory positions at various biotechnology companies in the San Francisco Bay area.

“Amy Levin is an extremely accomplished and highly respected regulatory affairs specialist with a stellar history of high performance across multiple organizations,” said Slone Partners President Tara Kochis. “She is a smart and passionate leader who will be a tremendous addition to the Mainz Biomed team as it moves forward with its aggressive plans to bring ColoAlert to market in the U.S.”

“Ms. Levin is an outstanding addition to our executive team and is well known as a strategic thinker, methodical problem solver, and inclusive people manager who is results-oriented,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “With these strong attributes and extensive professional experience, she will help drive our internal processes to support operational excellence as we execute our clinical trials and work toward FDA submission and approvals in the U.S.”

“I have spent a majority of my career in regulatory affairs and am excited to use my expertise and in-depth knowledge of the regulatory guidelines, landscape and processes to further advance ColoAlert with a focus on the U.S. as its key market as well as the company’s portfolio of cancer detection products,” said Levin.

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing and diverse life sciences and healthcare organizations – People Are Our Science®. Founded in 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established biotech, diagnostics, research tools, healthcare, precision medicine, medical device, and laboratory services companies. With national and global clients, Slone Partners uniquely and precisely provides an array of executive search and advisory services, including diversity, equity, and inclusion strategy, to innovative life sciences and healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT MAINZ BIOMED NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert is marketed across Europe and the United Arab Emirates. The Company is currently running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter, and Facebook.

Share article on social media or email:



Mercury Insurance to Celebrate ‘Community Hero’ at LA Kings Home Games


It’s incredible to be a part of the passionate LA Kings community,” said Erik Thompson, vice president and Chief Marketing Officer at Mercury Insurance. We want our ‘Community Hero’ to know that Mercury appreciates them by giving each Hero the experience of a lifetime.

Mercury Insurance (NYSE: MCY) is continuing its 60 years celebration of service to Southern California communities by returning to the hockey rink with its 2022-23 Los Angeles Kings partnership. This marks the 15th consecutive year the two have teamed up to give fans and policyholders unique experiences inside and outside of games.

Mercury Insurance and the LA Kings this season are unveiling a fan favorite with a power-play twist, “My First Game” series. The series features Kings players reminiscing about their first games. It’s viewable at https://www.mercuryinsurance.com/campaigns/my-first/kings and Mercury invites fans to share in the fun with their own first game experiences on social media.

Mercury Insurance asked some fan favorites about their first game memories, including: LA-native Trevor Moore, Viktor Arvidsson, and Mikey Anderson:

  • Trevor Moore: “It was a Kings game. I remember coming through the concourse and the alley, then seeing the ice open up. It was pretty special. I was pretty young, but I remember how it made me feel.”
  • Viktor Arvidsson: “It was a group of 3-4 friends that always went to the game. In Sweden, you either sit or stand as a fan so we were always standing at the glass. Just a feeling of going there with my friends and having fun.”
  • Mikey Anderson: “It was a Minnesota Wild game. I was about 5 years old. My brother and I were wearing Marián Gáborík jerseys. We tried to go to as many of those [games] as we could.”

“It’s incredible to be a part of the passionate LA Kings community,” said Erik Thompson, vice president and Chief Marketing Officer at Mercury Insurance. “Mercury has planned a special program this season to coincide with our 60 years of serving Southern California communities. We’ll also be honoring unsung heroes at Kings’ home games for all the work they do in the community. We want our ‘Community Hero’ to know that Mercury appreciates them by giving each Hero the experience of a lifetime.”

The Community Hero is a chance for the Kings and Mercury, with the help of the Make-A-Wish Foundation, to honor those everyday heroes we don’t always know are right in front of us. The first Community Heroes are:

  • Ollie is a vibrant six-year-old from Valencia, California. Experiencing the magic of Disney World is his biggest wish. Ollie will be joined at the Kings game with his mom Marissa, dad Kyle, and sister Oakley.
  • Rachana Shah, MD, is the Director of the Cancer and Blood Disease Institute’s Retinoblastoma Program at Children’s Hospital Los Angeles. She helps care for many young children that develop cancer in the eye and is leading research in the field.

“The Kings are always looking for ways to honor the real heroes of the community,” said Luc Robitaille, President of the Los Angeles Kings. “We’re excited to showcase how these individuals lift their communities.”

For more information on this year’s sponsorship, please visit http://www.mercuryinsurance.com.

About Mercury Insurance

Mercury Insurance (NYSE: MCY) is a multiple-line insurance carrier predominantly offering personal auto, homeowners and renters insurance through a network of independent agents in Arizona, California, Georgia, Illinois, Nevada, New Jersey, New York, Oklahoma, Texas and Virginia, as well as auto insurance in Florida. Mercury writes other lines of insurance in various states, including commercial, business owners and business auto, landlord, home-sharing, ride-hailing and mechanical protection insurance.

Since 1962, Mercury has provided customers with tremendous value for their insurance dollar by pairing ultracompetitive rates with excellent customer service. Mercury has earned “A” ratings from A.M. Best and Fitch, as well as ranking highest in the J.D. Power 2021 U.S. Insurance Digital Experience Study,SM recognized as one of the “Best Insurance Company in America for 2022” by Forbes and four consecutive “Best Auto Insurance Company” awards from Insure.com. For more information visit http://www.MercuryInsurance.com or follow the company on Twitter or Facebook.

###

Share article on social media or email:

Syner-G BioPharma Group Acquires RMC Pharmaceutical Solutions


Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients, today announced the acquisition of RMC Pharmaceutical Solutions (RMC). Based in Boulder, CO, RMC supports the outsourced CMC and Quality needs of biotech and pharma companies across multiple therapeutic areas.

The acquisition provides additional depth to Syner-G’s suite of pharmaceutical science services, adding impressive development experience in all biologic modalities including cell and gene therapy. The combined team offers an impressive range of process and analytical development services, regulatory strategy, regulatory submission support, and quality management services. For RMC, the acquisition provides biotech and pharma clients access to a full range of integrated development and regulatory services.

Syner-G and RMC have strong records of consistent growth and success in providing customized solutions to support the development of life enhancing and lifesaving therapeutics. The combination enhances their ability to deliver the highest caliber CMC services to pharma and biotech companies of all sizes on a global basis.

“I am very pleased to welcome the RMC team to Syner-G,” said Ron Kraus, chief executive officer, Syner-G BioPharma Group. “RMC’s Biologics experience and their ‘Responsive, Measured, and Creative’ approach to product development fits perfectly with Syner-G’s vision to be the trusted development partner to our clients, recognized globally for our strategic, innovative, and scientifically-driven approach.”

Led by founders, Timothy Joy and Scott Rudge, RMC has provided practical and science-driven CMC and Quality solutions to its clients for over 18 years.

“Our clients have come to expect high levels of critical thinking, informed by the best science and engineering, applied reliably, nimbly, and phase appropriately to solve problems and advance their programs,” said Scott Rudge, co-founder, chairman, and chief operating officer of RMC. “We know that’s exactly what they will continue to receive from Syner-G and I’m delighted to continue to play a key role in the combined business.” Timothy Joy, co-founder, president, and chief executive officer of RMC added, “In addition to the obvious benefits the combined organization presents to RMC’s clients, I’m excited about the future opportunities that being part of a larger organization offers to the RMC team.”

Financial terms of the transaction, which closed in January 2023, were not disclosed.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, visit http://www.synergbiopharma.com.

About RMC Pharmaceutical Solutions

Based in Boulder, CO, RMC specializes in providing CMC and quality management services for the pharmaceutical and biotech sector. For more information, visit http://www.rmcpharma.com.

Share article on social media or email:

Piezo Therapeutics Launches to Transform Delivery of Nucleic Acid Medicines


News Image

Piezo Therapeutics is advancing a novel delivery platform to improve the safety, affordability, and scalability of nucleic acid medicines.

Piezo Therapeutics launched with $2 million in seed funding from Open Philanthropy to develop its platform: a simple and affordable way of delivering RNA and DNA medicines, including vaccines and therapeutic proteins. Piezo’s platform combines electric pulses and microneedles to deliver nucleic acid medicines safely and efficiently while accelerating manufacturing, easing access, and minimizing costs.

“The COVID-19 pandemic has enabled incredible advances in mRNA vaccines and potential for future RNA therapeutics. However, these RNA-based medicines still face challenges with manufacturing, thermostability, safety, and access,” said Gaurav Byagathvalli, co-founder and CEO. “Piezo has a unique opportunity to address these challenges with a simple, affordable, and scalable platform enabling further translation of RNA, DNA, and other therapeutics.”

Novel Platform Building on Decades of Data

Piezo’s platform combines two key technologies that have been validated in pre-clinical and clinical models for over 25 years, namely the use of electric pulses and microneedles for drug delivery. Electric pulses have been shown to enhance gene expression of RNA and DNA constructs by 100-1000-fold, while microneedles have demonstrated painless and effective delivery of a broad range of biologics.

Current modes of administering electric pulses have numerous limitations associated with cost, manufacturing, patient administration, and tolerability, which have hindered their translation. “Piezo’s key innovation in generating electric pulses addresses each of these challenges,” said Mark Prausnitz, co-founder. “And when combined with microneedles, our technology enables improved safety and efficacy in a simple and scalable format.”

“We are excited about our partnership with Open Philanthropy, and our shared mission to improve patient access to these innovative treatments, globally,” said Saad Bhamla, co-founder.

Company Vision and Leadership

RNA therapeutics have made major advances but suffer from limitations associated with their delivery in the body. While lipid nanoparticles are used in current COVID vaccines, they present issues including high cost, manufacturing complexity, and poor stability. Electric pulses can also provide effective delivery, but current approaches involve devices that have even higher costs and complexity.

To enable next-generation RNA and DNA medicines, Piezo is advancing its platform integrating a piezoelectric pulse generator and microneedles to address these challenges.

While this platform has high applicability for vaccines (Piezo’s immediate focus), it is designed for a broad array of nucleic acid therapeutics. Piezo plans to partner with a range of companies across diverse therapeutic modalities including vaccines, immunotherapies, therapeutic proteins, and dermal gene therapies.

Piezo will be led by Gaurav Byagathvalli, who will serve as chief executive officer and a member of the board of directors.

Piezo’s highly experienced board of directors also includes:


  • Mark Prausnitz, Ph.D.: Prausnitz is a Regents’ Professor and Regents’ Entrepreneur in Chemical & Biomolecular Engineering at Georgia Tech. He is a Fellow of the National Academy of Inventors and has co-founded eight privately held or publicly traded companies in pre-clinical, clinical and product stages of commercialization.
  • Saad Bhamla, Ph.D.: Bhamla is an Assistant Professor of Chemical & Biomolecular Engineering at Georgia Tech. He is a prolific inventor and has developed numerous biomedical devices with applications in global health.
  • Cynthia Sundell, Ph.D.: Sundell has over 15 years drug development executive management experience in the US and Europe. She is currently a Principal in Georgia Tech’s VentureLab where she stewards promising commercialization opportunities arising from Georgia Tech’s life science intellectual property portfolio.


To support the development and translation of Piezo-delivered medicines, the company is conducting pre-clinical studies in collaboration with academic institutes, while working with industry partners to co-develop products that deliver their therapeutics with Piezo’s technology.

About Piezo Therapeutics

Piezo Therapeutics aims to transform the delivery of nucleic acid medicines to enable improved safety, affordability, and scalability. Piezo is developing a uniquely engineered platform that uses electric pulses and microneedles to deliver a broad range of therapeutics inside the body. Its piezoelectric technology offers improved safety and efficacy, and is simple, cost-effective, and rapid to produce at scale. Founded by experts in the field of drug delivery and commercial translation, Piezo’s diverse team aims to help translate the next generation of nucleic acid medicines. For more information, please visit http://www.piezotx.com or email partnerships@piezotx.com.

Share article on social media or email: